A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report

BACKGROUND: In general, dexamethasone is a required component drug in various combination chemotherapies for treating multiple myeloma, and its efficacy has been widely recognized. However, administration of dexamethasone is known to cause various adverse effects including hyperglycemia which requir...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemori, Nobuo, Imai, Goro, Hoshino, Kazuo, Ooi, Akishi, Kojima, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816938/
https://www.ncbi.nlm.nih.gov/pubmed/29454372
http://dx.doi.org/10.1186/s13256-017-1550-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816938/
https://www.ncbi.nlm.nih.gov/pubmed/29454372
http://dx.doi.org/10.1186/s13256-017-1550-6

Ejemplares similares